Immunocore Holdings PLC has unveiled its strategic priorities for 2025, including plans to expand access to its Kimmtrak (tebentafusp) drug for metastatic uveal melanoma patients in more countries.

"Millions of packages moved away from SurePost and the United States Postal Service and returned to UPS package cars this month, now being sorted and delivered by hardworking UPS Teamsters." ...

One of the best ways to improve the customer’s shopping experience is with package inserts; customer package inserts can be designed to improve the customer’s unpackaging experience greatly, which in ...

The Company also highlights the potential of its melanoma franchise building on KIMMTRAK’s performance and reveals details of IMC-U120AI (CD1a x PD1), its first non-HLA restricted candidate. This ...

Immunocore Holdings plc announced its strategic priorities for 2025, focusing on expanding access to its melanoma treatment, KIMMTRAK (tebentafusp), and advancing its clinical pipeline in oncology ...

The Company also highlights the potential of its melanoma franchise building on KIMMTRAK’s performance and reveals details of IMC-U120AI (CD1a x PD1), its first non-HLA restricted candidate.

The Company also highlights the potential of its melanoma franchise building on KIMMTRAK’s performance and reveals details of IMC-U120AI its first non-HLA restricted candidate. This second ...

NEW YORK – Immunocore on Friday announced several strategic priorities and pipeline updates including plans to grow the use of Kimmtrak (tebentafusp) in HLA-A*02:01-positive metastatic uveal melanoma.

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

has the HLA‑A*02:01 genotype and is unresectable (cannot be surgically removed) or metastatic (has spread to other parts of the body). Your healthcare professionals should give you clear information, ...